Skip to content

Assessment of effect of crocin on Covid-19 patients

Assessment of additive effect of crocin in Covid-19 patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210203050233N1
Enrollment
60
Registered
2021-04-14
Start date
2021-02-19
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: In this group, patients (n=30) will receive 15 mg crocin tablet (Krocina™, made by Sami Saz Company) , twice a day, for 14 days. Intervention 2: Control group: In t

Sponsors

National Institute for Medical Research Development (NIMAD)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed cases of Covid-19 2. Patients admitted to hospital Covid-19 general wards 3. Being 20-60 years old, of either sex. 4. Ability to sallow oral medication. 5. Patients without immunodeficiency and gastrointestinal disorders 6. Not being pregnant/breast feeding

Exclusion criteria

Exclusion criteria: 1. Being allergic to saffron/crocin 2. Inability to swallow oral medication during admission

Design outcomes

Primary

MeasureTime frame
Cell blood count (CBC). Timepoint: on days 0, 7 and 14. Method of measurement: CBC will be measured by auto analyzer. Differential cell counts will be performed in stained peripheral blood smear (Wright-Giemsa) under light microscope.;Serum C-reactive protein (CRP) level. Timepoint: on days 0, 7 and 14. Method of measurement: CRP serum level will be measured using standard ELISA kits.;TNF-a serum level. Timepoint: on days 0, 7 and 14. Method of measurement: TNF-a serum level will be measured using standard ELISA kits.;LDH serum level. Timepoint: on days 0, 7 and 14. Method of measurement: LDH serum level will be measured using standard ELISA kits.;Erythrocyte sedimentation rate (ESR). Timepoint: on days 0, 7 and 14. Method of measurement: Sedimentation Analyzer.

Secondary

MeasureTime frame
A. Clinical signs and symptoms: fever, cough, dyspnea, myalgia, chill, headache, respiratory rate, weakness, chest pain, nausea, vomiting, gastro-intestinal manifestations, O2 saturation. Timepoint: On days 0 and 14. Method of measurement: Clinical signs and symptoms will be recorded using the checklist.;Lung involvement. Timepoint: On days 0 and 14. Method of measurement: Lung radiography assessment will be performed by lung high-resolution computed tomography (HRCT).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Rezaee

Mashhad University of Medical Sciences

RezaeeRA@mums.ac.ir+98 51 3802 2097

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026